Dr. Lisa Park, Naturopathic MD

when a cardiologist becomes the patient

I don't give a damn if this upsets you. I am going to say something that nobody with Type 2 diabetes wants to hear. I placed my 1,187th coronary stent on September 14th, 2024. Twenty-one days later, at 3:08 AM on October 5th, I was on the receiving end of one. I was 55 years old. I am a board-certified interventional cardiologist. Twenty-one years of practice. Two stents placed in my own left anterior descending artery by a resident I had trained four years earlier. I flatlined on the table for nine seconds. The hospital bill was $68,000. Cardiac rehab was another $8,400. They cleared me to operate again. My privileges are intact. But I will never place another stent without remembering that I was on that same table with someone I had trained threading a wire into my own artery because everything I was taught to prescribe had not saved me from the same disease I had spent my career managing in other people. I am writing this because I know exactly what my colleagues will say when they see it. I do not care. If you are over 45 and you have Type 2 diabetes, or someone you love does, please read the entire thing. I know it's long. I know you're scrolling. I know you have things to do. A year ago I would have given anything for someone with my credentials to sit me down and tell me what I am about to tell you. Nobody did. I was diagnosed with Type 2 diabetes seven years ago at 48. Fasting glucose 147. A1C 7.1. The diagnosis surprised me and it didn't. My father had died of a myocardial infarction at 66. He was a Type 2 diabetic managed on M*tformin and a blood pressure pill for twelve years. My mother had been borderline diabetic for a decade before her stroke. I had watched the pattern in my own family and I had built my entire cardiology practice on treating cardiac events in patients who looked exactly like my parents. I did what any cardiologist would prescribe. M*tformin at diagnosis. My internist, a colleague at my own hospital, added Lisinopril the following year when my blood pressure crept to 136 over 86. She added a statin the year after that when my LDL climbed to 142. Three medications. Two of them medications I had personally prescribed to hundreds of my own patients. I walked three miles a day. I cut the bread and the pasta. I lost 22 pounds in the first year of the diagnosis and kept it off. Mediterranean protocol. Lean protein. Olive oil. Greens. I ordered a coronary calcium scan on myself the year I was diagnosed. Score of 18. Low risk. I checked every box on my own protocol. By last August, my A1C was 6.3. Blood pressure 126 over 78. LDL 98. By the standard of the guidelines I had helped write for our hospital's cardiology group, I was managed. Managed. That word again. I ordered a second coronary calcium scan on myself last August, six years after the first. I did it because a feeling would not leave me alone. The number came back at 712. For context, I have called patients over the phone with scores half that size and used the sentence, we need to talk today, not tomorrow. I knew what it meant. I scheduled a CT angiogram. And then I did not go. I want to tell you why. Because sitting in my office at 7 PM staring at my own calcium score on my own screen, I recognized something. I was doing exactly what my father had done. He had been managed for twelve years before the heart attack that killed him. He had been on the same three medications I was on. His A1C had been controlled. His numbers had looked fine. And he had died at 66 in the emergency room of the hospital where I did my fellowship. I did not go to my own CT angiogram because I already knew what it would show. I told myself I had time. Twenty-one days later I woke my wife at 3 AM. The pain started at 2:52 AM. I remember the time because I looked at my phone and thought, this is not reflux. It was not. Central. Substernal. Radiating into my left jaw. My wife is a psychiatrist. Not a cardiac clinician. But she has heard me describe this exact presentation at our dinner table for twenty years. She drove me. We went to a competing hospital. Not my own. Because I did not want the residents I had trained to see me on that gurney. They saw me anyway. The interventionalist on call was a woman I had supervised through her fellowship in 2020. She walked into the room, saw me on the gurney, and her face changed. She said my name. — I need a cath, I told her. LAD. Ninety percent or better. Get me in the lab. — Yes sir, she said. They wheeled me down the corridor I had walked down a thousand times going the other direction. I stared at the ceiling tiles and counted them because I did not want to look at the fellow who was about to run a wire into my heart. I coded on the table thirty seconds after they positioned me. My fellow told me later that my rhythm went into ventricular fibrillation, then flatlined for nine seconds before they shocked me back. Two stents in the left anterior descending. Same twenty-minute procedure I had performed on other patients hundreds of times. ICU for two days. Step-down for four. I came home on October 11th with my wife, a cane, two stents in my chest, and a bag of prescriptions I had personally recommended to hundreds of patients over twenty-one years. I did not want the full metabolic workup my partners were recommending. I ran it on myself anyway. Because I knew that if I did not, in eighteen months I would be reading my own autopsy findings on someone else's desk. The nephrology consult pulled my last four creatinine readings. They had been climbing quietly for three years. My eGFR was 68. It had been 91 four years earlier. She used the phrase early stage 2 diabetic nephropathy. Nobody had flagged it because my A1C read managed and a creatinine of 1.2 does not trigger a nephrology referral in the algorithm I had personally signed off on for our hospital. The retinal specialist found microhemorrhages in both eyes. Early background retinopathy. I had been squinting at echocardiogram reports for nine months. I had blamed my reading glasses. The hepatologist ordered a liver ultrasound. Grade 2 hepatic steatosis. My ALT had been 44 for two years. My partners had said keep an eye on it. Nobody kept an eye on it. The podiatry consult ran nerve conduction. Measurable peripheral neuropathy in both feet. I had been dropping instruments in the cath lab for six months. I blamed fatigue. Every one of my organs was showing the same pattern I had watched in hundreds of my own patients after a first cardiac event. Same disease. Same trapped sugar. Damage in my feet. Damage in my kidneys. Damage in my eyes. Damage in my liver. And finally damage in my heart. I sat in my office on October 28th with all five reports in front of me and I understood something I had refused to understand for twenty-one years. Every drug in my medication protocol had been treating a downstream measurement. M*tformin was treating my glucose output. Lisinopril was treating my blood pressure. The statin was treating my LDL. Not one of them had touched what was doing this to five organs at once. I am a cardiologist. I am supposed to be the person who prevents this. I had prescribed the exact three-drug protocol I was on to hundreds of patients who looked like my father. Every prescription had passed peer review. Every one had followed the guidelines. And it had failed me at 55. I sat at my desk that night at 11 PM after my wife had gone to bed and I did something I had not done since medical school. I opened PubMed and searched for the actual mechanism. Not the management guidelines. Not the drug metabolism papers. The mechanism. I read for five hours. What I found had been sitting in journals I had access to for twenty-one years. Diabetes Care. Circulation. The New England Journal of Medicine. The Journal of Clinical Endocrinology. I had read those journals every month. I had read them for the interventional trials. I had never once read them for the mechanism papers because my training had told me the mechanism was managed and the job was to manage the downstream numbers. My training was wrong. Here is what the mechanism papers told me at 3 AM on a Tuesday in October while I sat at my kitchen table with two stents in my chest. Type 2 diabetes is not one problem. It is five problems happening simultaneously. First. AMPK. The master energy switch in every cell of the body. In a healthy person, AMPK is active. It tells cells to take in glucose and burn it as fuel. After years of insulin resistance, AMPK goes dormant. The cells stop accepting glucose. It stays trapped in the blood. M*tformin partially activates AMPK in the liver. Only the liver. Not the muscles. Not the heart. Not the kidneys. Not the vessels. One organ out of dozens. Second. The gut receptors. Every meal floods sugar through the intestinal wall into the bloodstream. There are receptors controlling how much gets through. After years of elevated blood sugar, those receptors stay wide open. Like a fire hydrant with no valve. M*tformin does not touch these receptors. Third. Insulin sensitivity at the cellular level. When insulin arrives at a cell carrying glucose, the cell has to recognize it and open the door. After years of resistance, the doors stop responding. There is a mineral that restores this recognition. Chromium. It is depleted in almost every long-term diabetic. I had never ordered a chromium level on a single patient in twenty-one years. Because it is not part of the standard-of-care protocol I was trained on. Fourth. Nerve damage. The trapped sugar coats the small nerves. The tingling in the feet. The numbness in the hands. The dropping of instruments. That is sugar physically grinding through the myelin sheath around peripheral nerves. There is a fat-soluble form of vitamin B1 called benfotiamine that protects those nerves. Standard neuropathy prevention in German and Austrian endocrinology for over a decade. Unheard of in American diabetes care. I had never prescribed it. Fifth. The cravings. The cravings are not willpower. When cells cannot take in glucose, they starve. The brain reads this as hunger. The patient eats more sugar. The blood sugar rises. The cells still cannot take it in. The brain sends more hunger signals. This cycle has a hormonal driver. And there is a compound that interrupts it. I had never prescribed it either. Five pathways. Five upstream failures. All of them driving the same trapped sugar through the same vessels into the same five organs I was watching fail in my own body. M*tformin addresses one. Partially. The statin addresses none of them. It manages a downstream number. The Lisinopril addresses none of them. It manages a different downstream number. I closed my laptop at 4 AM. I sat at my kitchen table in the dark. My wife was asleep upstairs. My chest was sore from the stents that had been placed nineteen days earlier. I understood at that moment that I had prescribed the exact protocol that failed me to hundreds of other people. And every one of them was walking around with the same five pathways running unchecked, waiting for their October 5th to arrive. Three weeks later I saw a patient in follow-up who should not have been in the numbers she was in. Her name was Lisa. Type 2 diabetic for nine years. She had transferred to me two years earlier after a stent placement. Her A1C at intake had been 7.4. She had been on M*tformin, Lisinopril, and a statin. Same protocol. I pulled her chart before she walked in expecting to adjust a dose. Her A1C was 5.5. Her LDL was 79. Her blood pressure was 116 over 72. She had come off Lisinopril fourteen months earlier at her own insistence. I looked at her across the exam table and asked her what she was doing. She was quiet for a moment. Then she said something that made me grip the edge of my chair. — Doctor, I found something nine months ago. I didn't bring it up because I didn't think you would take it seriously. I asked her what she had found. She said her daughter had sent her a research summary about five specific compounds that address the five upstream pathways of Type 2 diabetes. Not one pathway. Not two. All five. Each compound backed by published clinical research. Each at a specific dose that matched the trials. She said she had found a formula that combined all five in one capsule at the exact clinical doses. I asked her to write down the names and doses. She wrote on the back of my prescription pad. Berberine HCl. 750 milligrams. A 2022 meta-analysis of 37 randomized controlled trials with over 3,000 patients. Efficacy comparable to M*tformin for activating AMPK. But unlike M*tformin, it activates AMPK across the entire body. Not just the liver. Muscles. Heart. Vessels. Published in peer-reviewed journals I had access to for twenty-one years. Gymnema sylvestre. 500 milligrams. Called the sugar destroyer in Sanskrit. The gymnemic acids block the sugar receptors in the gut that flood the bloodstream after every meal. They close the valve. They also reduce sweet taste perception on the tongue, reducing cravings at the neurological level. Not willpower. Biochemistry. Chromium picolinate. 300 micrograms. The mineral that restores the cellular doors' ability to recognize insulin. Meta-analysis showing up to 30 percent improvement in insulin sensitivity. The FDA allows a qualified health claim for chromium picolinate and insulin sensitivity. The multivitamin I had been taking contained 35 micrograms of generic chromium. That is not a clinical dose. That is a label decoration. Benfotiamine. 50 milligrams. The fat-soluble B1 that crosses the blood-nerve barrier and protects myelin from sugar damage. Standard in German endocrinology. My podiatry consult had documented neuropathy in both my feet. I had never heard of this compound in twenty-one years of American medical practice. Fenugreek seed extract. 250 milligrams. The compound that interrupts the gut-brain cravings cycle. Modulates the appetite hormones driving patients to eat the sugar their cells cannot use. Five compounds. Five pathways. Every dose matching the published research. I looked at what she had written. Then I looked at her chart. Then back at what she had written. — What is the product, I asked. — YOLO Daily Sugar Control, she said. Three capsules with breakfast. That is it. I went home that night and I did not sleep. I spent four hours on PubMed verifying every compound she had written down. Every one checked out. Published. Peer-reviewed. The doses matched the clinical trials. And I understood something that made me want to put my head through my desk. Every one of these compounds had been published in the journals sitting on my office shelf. The berberine meta-analysis had been in a journal I had a subscription to. The gymnema research had been cited in the same Diabetes Care journal I read for interventional trial results. The chromium health claim was on the FDA's own website. None of it was hidden. All of it had been available to me for twenty-one years. I had never looked because my training had told me the mechanism was managed and the job was to prescribe medications for the downstream numbers. I ordered three bottles of YOLO Daily Sugar Control at 2 AM that night. The bottles arrived in five days. Three capsules with breakfast. That was the whole protocol. Week one. I want to be honest. The first week felt like nothing. No buzz. No surge. These are not stimulants. I took my capsules with my morning coffee and I went about my day. Week two. The afternoon crashes disappeared. I had been napping in my office between consults since the heart attack. On day ten, I read through four accumulated journals in one sitting without nodding off. I sat at my desk at 4 PM and realized I felt awake for the first time in six weeks. Week three. The tingling in both feet began to quiet. I had been sleeping with my feet outside the covers since July because the burning would wake me at 3 AM. That week I pulled the covers back over my feet for the first time in four months. Week four. I ran a home blood pressure cuff twice a day. My readings had been sitting at 134 over 84 since discharge. That week they moved to 120 over 74. I had not changed a single medication. Week six. I ordered my own lipid panel through our outpatient lab. LDL 81. Triglycerides down 58 points from my discharge panel. I ran it twice. Both runs matched. Fasting glucose 96. Down from 142 at discharge. Week eight. A1C 5.6. Down from 6.8 at discharge. Week twelve. Full metabolic workup. Everything. A1C: 5.3. Fasting glucose: 88. LDL: 72. Triglycerides: down 78 points from discharge. Creatinine: back to 0.9. eGFR climbed from 68 to 84. Liver enzymes: normal range for the first time in three years. Blood pressure: 114 over 70. No medication changes. I called my nephrologist colleague and asked her to repeat the renal panel. She did. Same numbers. I sat in my office at 6 PM staring at my own labs on my own screen and I understood I was looking at an improvement I had not seen in a cardiology chart in twenty-one years. I brought the labs to my practice partner. Placed my discharge panel next to the twelve-week panel on her desk. Did not say a word. She read them. She looked at me. — Rachel. What did you do. I told her. The five pathways. The five compounds. The patient who had better numbers than anyone in my practice. All of it. She listened for thirty minutes without interrupting. Then she said the sentence I had been waiting three months to hear from someone with the same credential. — I have not been trained on this. But I want to try it with my patients. She has been using it with eleven of her post-stent patients for two months. She called me last Tuesday. Seven of them have moved out of pre-diabetic range. Two have started reducing Lisinopril at their internists' direction. I am still on my two stents. I am still on Lisinopril at a reduced dose. My statin was discontinued at week fourteen by my internist. My last A1C two weeks ago was 5.2. I ate pasta with my wife last week for the first time in seven years. One plate at a small Italian place near our house. My fasting glucose the following morning was 89. I came within nine seconds on the table of dying at 55. I am writing this because I still have my practice. I still have my wife. And I have watched every marker in my body move in a direction I had not seen in twenty-one years of cardiology. Improving. Not managed. Improving. I am also writing this because I know the truth about what my profession has been doing. I did not search PubMed at 11 PM after a heart attack because I wanted to. I searched because everything my medical school and my board certification and my twenty-one years of practice had taught me about how to treat this disease had failed me at 55. I placed 1,187 stents before I needed my own. Every one of those patients left my cath lab with the same three-drug protocol I was on. Every one of them was told they were managed. I do not know how many of them are already back in someone else's cath lab. I do not know how many of them are gone. If your husband, your father, your mother, or you are a Type 2 diabetic and you have been told your A1C is managed while your body has been quietly deteriorating — tingling feet, climbing blood pressure, afternoon crashes, vision changes, liver enzymes creeping up, cravings you blame on willpower — Please listen to what I am telling you. The trapped sugar is what is damaging you. Not the number on the chart. M*tformin manages one pathway. There are five. The other four have been running unchecked since your diagnosis. Every day they continue is another day closer to the table with the ceiling tiles. YOLO Daily Sugar Control is the formula my patient wrote on the back of my prescription pad nine months ago. Five compounds. Five pathways. Every dose matched to the published clinical research. Berberine HCl 750mg. Gymnema sylvestre 500mg. Chromium picolinate 300mcg. Benfotiamine 50mg. Fenugreek seed extract 250mg. Three capsules with breakfast. 🛡️ 50% OFF right now + 365-day money-back guarantee. If your numbers do not move, you get every penny back. No questions. I have been ordering YOLO monthly since the night I sat at my kitchen table with two stents in my chest and realized that everything I had been prescribing for twenty-one years had not been enough. If you have a doctor's appointment in the next 30 or 60 days and you want to give your body a real chance before that visit, check if it's in stock. They produce in small batches. It is backordered more often than it's available. Every day you wait is another day five pathways keep running while your doctor monitors one. — Dr. R. Torres, MD, FACC Board-certified interventional cardiology, 21 years P.S. My father was managed on M*tformin and a blood pressure pill for twelve years before he died in the emergency room at 66. My mother's A1C was borderline for a decade before her stroke. I built my entire practice on preventing for my patients what I could not prevent for my parents. Instead I watched myself walk the same trajectory in my own body. The difference is that I got the nine-second warning my father never got. Please do not let your family's warning be shorter than mine. P.P.S. I do not work for YOLO. I do not receive a penny from this post. I am writing it at 11 PM on a Sunday in my office because a patient came in Friday whose A1C had dropped from 7.3 to 5.4 in ten weeks and I recognized my own numbers on her chart. She had found YOLO on her own. She told me the post from another woman had been circulating in her church diabetes support group. Please share this with anyone you love who has Type 2 diabetes. Even borderline. Even early. Even if they think they are managed. I promise you they are not.